Literature DB >> 30169897

Modifiable vascular risk factors, white matter disease and cognition in early Parkinson's disease.

L M Chahine1, C Dos Santos2, M Fullard2, C Scordia2, D Weintraub2,3, G Erus4, L Rosenthal5, C Davatzikos4, C T McMillan2.   

Abstract

BACKGROUND AND
PURPOSE: Dementia in Parkinson's disease (PD) is common and disabling. Identification of modifiable risk factors for it is essential. Vascular risk factors (VRFs) may be associated with cognitive decline in early PD. Biomarkers that serve as surrogates of the long-term effect of VRFs on PD are needed. To that end, we aimed to quantitate white matter hyperintensities (WMH) in early PD, measure associations with VRFs and examine relationships between WMH and longitudinal cognition.
METHODS: Participants in the Parkinson's Progression Markers Initiative study (141 patients with PD, 63 healthy controls) with adequate baseline structural brain magnetic resonance imaging data were included. Hypertension and diabetes history, and body mass index were combined to create a vascular risk score. WMH were quantitated via automated methods. Cognition was assessed annually with a comprehensive test battery.
RESULTS: In the PD group, vascular risk score was associated with WMH for total brain (β = 0.210; P = 0.021), total white matter (β = 0.214; P = 0.013), frontal (β = 0.220; P = 0.002) and temporal (β = 0.212; P = 0.002) regions. Annual rate of change in global cognition was greater in those with higher vascular risk score (β = -0.040; P = 0.007) and greater WMH (β = -0.029; P = 0.049). Higher temporal WMH burden was associated with great decline over time in verbal memory (β = -0.034; P = 0.031).
CONCLUSIONS: In early PD, modifiable VRFs are associated with WMH on brain magnetic resonance imaging. Temporal WMH burden predicts decline in verbal memory. WMH may serve as a surrogate marker for the effect of VRFs on cognitive abilities in PD.
© 2018 EAN.

Entities:  

Keywords:  Parkinson's disease; cerebrovascular diseases; cognitive disorders

Mesh:

Year:  2018        PMID: 30169897      PMCID: PMC6329649          DOI: 10.1111/ene.13797

Source DB:  PubMed          Journal:  Eur J Neurol        ISSN: 1351-5101            Impact factor:   6.089


  34 in total

1.  Measuring brain lesion progression with a supervised tissue classification system.

Authors:  Evangelia I Zacharaki; Stathis Kanterakis; R Nick Bryan; Christos Davatzikos
Journal:  Med Image Comput Comput Assist Interv       Date:  2008

2.  Cognitive correlates of white matter lesion load and brain atrophy: the Northern Manhattan Study.

Authors:  Chuanhui Dong; Nooshin Nabizadeh; Michelle Caunca; Ying Kuen Cheung; Tatjana Rundek; Mitchell S V Elkind; Charles DeCarli; Ralph L Sacco; Yaakov Stern; Clinton B Wright
Journal:  Neurology       Date:  2015-07-08       Impact factor: 9.910

3.  The influence of vascular risk factors on cognitive function in early Parkinson's disease.

Authors:  Maxime Doiron; Mélanie Langlois; Nicolas Dupré; Martine Simard
Journal:  Int J Geriatr Psychiatry       Date:  2017-05-16       Impact factor: 3.485

4.  Cardiovascular risk factors and cognitive decline in middle-aged adults.

Authors:  D Knopman; L L Boland; T Mosley; G Howard; D Liao; M Szklo; P McGovern; A R Folsom
Journal:  Neurology       Date:  2001-01-09       Impact factor: 9.910

5.  Smoking and cognitive function in Parkinson's disease.

Authors:  Marc G Weisskopf; Francine Grodstein; Alberto Ascherio
Journal:  Mov Disord       Date:  2007-04-15       Impact factor: 10.338

Review 6.  Smoking and Parkinson's disease: systematic review of prospective studies.

Authors:  Mohamed Farouk Allam; Michael J Campbell; Albert Hofman; Amparo Serrano Del Castillo; Rafael Fernández-Crehuet Navajas
Journal:  Mov Disord       Date:  2004-06       Impact factor: 10.338

7.  Neuropathologic basis of white matter hyperintensity accumulation with advanced age.

Authors:  Deniz Erten-Lyons; Randall Woltjer; Jeffrey Kaye; Nora Mattek; Hiroko H Dodge; Sarah Green; Huong Tran; Diane B Howieson; Katherine Wild; Lisa C Silbert
Journal:  Neurology       Date:  2013-08-09       Impact factor: 9.910

8.  MUSE: MUlti-atlas region Segmentation utilizing Ensembles of registration algorithms and parameters, and locally optimal atlas selection.

Authors:  Jimit Doshi; Guray Erus; Yangming Ou; Susan M Resnick; Ruben C Gur; Raquel E Gur; Theodore D Satterthwaite; Susan Furth; Christos Davatzikos
Journal:  Neuroimage       Date:  2015-12-08       Impact factor: 6.556

9.  Influence of hypertension on neurocognitive domains in nondemented Parkinson's disease patients.

Authors:  Jacob D Jones; Charles Jacobson; Martina Murphy; Catherine Price; Michael S Okun; Dawn Bowers
Journal:  Parkinsons Dis       Date:  2014-01-23

10.  Parietal white matter lesions in Alzheimer's disease are associated with cortical neurodegenerative pathology, but not with small vessel disease.

Authors:  Kirsty E McAleese; Lauren Walker; Sophie Graham; Elisa L J Moya; Mary Johnson; Daniel Erskine; Sean J Colloby; Madhurima Dey; Carmen Martin-Ruiz; John-Paul Taylor; Alan J Thomas; Ian G McKeith; Charles De Carli; Johannes Attems
Journal:  Acta Neuropathol       Date:  2017-06-21       Impact factor: 17.088

View more
  20 in total

1.  White Matter Hyperintensities in the Synucleinopathies: Orthostatic Hypotension, Supine Hypertension, or Both?

Authors:  Horacio Kaufmann; Jose-Alberto Palma
Journal:  Mov Disord Clin Pract       Date:  2020-07-18

Review 2.  The Neuropsychiatry of Parkinson Disease: A Perfect Storm.

Authors:  Daniel Weintraub; Eugenia Mamikonyan
Journal:  Am J Geriatr Psychiatry       Date:  2019-03-09       Impact factor: 4.105

3.  Cognitive Performance is Associated with Altered Cerebral Hemodynamics Assessed by Transcranial Ultrasound in Parkinson's Disease.

Authors:  Yi-Lun Ge; Si-Yi Gong; Pu-Zhi Wang; Jia-Hui Yan; Wen Li; Jin-Ru Zhang; Hong Jin; Sheng Zhuang; Lei Hu; Chang-Wei Ding; Ya-Ping Yang; Fen Wang; Dan Li; Jing Chen; Cheng-Jie Mao; Ying-Chun Zhang; Kai Li; Chun-Feng Liu
Journal:  Neuropsychiatr Dis Treat       Date:  2022-07-12       Impact factor: 2.989

Review 4.  Morphological basis of Parkinson disease-associated cognitive impairment: an update.

Authors:  Kurt A Jellinger
Journal:  J Neural Transm (Vienna)       Date:  2022-06-20       Impact factor: 3.850

5.  Obstructive Sleep Apnea and Other Vascular Risk factors' Impact on Non-Motor Symptoms in Parkinson's Disease.

Authors:  Bruna Meira; Marco Fernandes; Manuel Salavisa; Marlene Saraiva; Laurete Conceição; Cláudia Borbinha; Filipa Ladeira; João Pedro Marto; Raquel Barbosa; Marcelo Mendonça; Paulo Bugalho
Journal:  Mov Disord Clin Pract       Date:  2022-07-06

6.  Statistically Defined Parkinson's Disease Executive and Memory Cognitive Phenotypes: Demographic, Behavioral, and Structural Neuroimaging Comparisons.

Authors:  Samuel J Crowley; Guita Banan; Manish Amin; Jared J Tanner; Loren Hizel; Peter Nguyen; Babette Brumback; Katie Rodriguez; Nikolaus McFarland; Dawn Bowers; Mingzhou Ding; Thomas A Mareci; Catherine C Price
Journal:  J Parkinsons Dis       Date:  2021       Impact factor: 5.568

Review 7.  Parkinson disease-associated cognitive impairment.

Authors:  Dag Aarsland; Lucia Batzu; Glenda M Halliday; Gert J Geurtsen; Clive Ballard; K Ray Chaudhuri; Daniel Weintraub
Journal:  Nat Rev Dis Primers       Date:  2021-07-01       Impact factor: 52.329

8.  Modifiable Comorbidities Associated with Cognitive Decline in Parkinson's Disease.

Authors:  Emily Forbes; Thomas F Tropea; Sneha Mantri; Sharon X Xie; James F Morley
Journal:  Mov Disord Clin Pract       Date:  2021-01-20

Review 9.  Cognitive Impairment in Parkinson's Disease: Epidemiology, Clinical Profile, Protective and Risk Factors.

Authors:  Paulina Gonzalez-Latapi; Ece Bayram; Irene Litvan; Connie Marras
Journal:  Behav Sci (Basel)       Date:  2021-05-13

10.  Cognitive and motor correlates of grey and white matter pathology in Parkinson's disease.

Authors:  Mahsa Dadar; Myrlene Gee; Ashfaq Shuaib; Simon Duchesne; Richard Camicioli
Journal:  Neuroimage Clin       Date:  2020-07-17       Impact factor: 4.881

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.